1999•PubMedRequires access

Pharmacokinetics of gliquidone, glibenclamide, gliclazide and glipizide in middle-aged and aged subjects.

Philippe Courtois, Azize Şener, C Herbaut, A Turc, W J Malaisse

Open publisher page 10 citations

Abstract

Six middle-aged (42-59 years old) and six aged (71-75 years old) subjects received each, on separate days, an oral administration of gliquidone (30 mg), glibenclamide (5 mg), gliclazide (80 mg) and glipizide (5 mg). The plasma concentration of the drugs was measured before and at eight times (60 min to 24 h) thereafter. The half-life of gliclazide was higher than that of the other three hypoglycemic agents in middle-aged subjects and was the sole to be significantly increased in aged subjects. There is no obvious difference between sulfonylureas eliminated mainly by either the kidney (glibenclamide, gliclazide, glipizide) or the liver (gliquidone) in terms of the influence of aging upon their clearance.

About this research paper

What this paper is about

Six middle-aged (42-59 years old) and six aged (71-75 years old) subjects received each, on separate days, an oral administration of gliquidone (30 mg), glibenclamide (5 mg), gliclazide (80 mg) and glipizide (5 mg). The plasma concentration of the drugs was measured before and at eight times (60 min to 24 h) thereafter. The half-life of gliclazide was higher than that of the other three hypoglycemic agents in middle-aged subjects and was the sole to be significantly increased in aged subjects. There is no obvious difference between sulfonylureas eliminated mainly by either the kidney (glibenclamide, gliclazide, glipizide) or the liver (gliquidone) in terms of the influence of aging upon their clearance.

Why it matters

OpenAlex reports 10 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Six middle-aged (42-59 years old) and six aged (71-75 years old) subjects received each, on separate days, an oral administration of gliquidone (30 mg), glibenclamide (5 mg), gliclazide (80 mg) and glipizide (5 mg). The plasma concentration of the drugs was measured before and at eight times (60 min to 24 h) thereafter. The half-life of gliclazide was higher than that of the other three hypoglycemic agents in middle-aged subjects and was the sole to be significantly increased in aged subjects. There is no obvious difference between sulfonylureas eliminated mainly by either the kidney (glibenclamide, gliclazide, glipizide) or the liver (gliquidone) in terms of the influence of aging upon their clearance.

Key concepts: Gliclazide, Glipizide, Glibenclamide, Pharmacokinetics, Medicine, Internal medicine, Diabetes mellitus, Pharmacology

Related papers

Back to paper searchBrowse research topicsOriginal source
Pharmacokinetics of gliquidone, glibenclamide, gliclazide and glipizide in middle-aged and aged subjects. — Research Paper | ScholarLens